Literature DB >> 11950722

Drug firms hype disease as sales ploy, industry chief claims.

Ray Moynihan.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11950722      PMCID： PMC1122820          DOI： 10.1136/bmj.324.7342.867

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Is it ethical to use enhancement technologies to make us better than well?

Authors:  Arthur Caplan; Carl Elliott
Journal:  PLoS Med       Date:  2004-12       Impact factor: 11.069

Review 2.  Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.

Authors:  Johanna Daubner; Muhammad Imran Arshaad; Christina Henseler; Jürgen Hescheler; Dan Ehninger; Karl Broich; Oliver Rawashdeh; Anna Papazoglou; Marco Weiergräber
Journal:  Neural Plast       Date:  2021-01-13       Impact factor: 3.599

3.  Functional Somatic Syndromes: Emerging Biomedical Models and Traditional Chinese Medicine.

Authors:  Steven Tan; Kirsten Tillisch; Emeran Mayer
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.